RSV vaccine in development: Assessing the potential cost-effectiveness in the Dutch elderly population

Vaccine

Volumn 31, Issue 52, 2013, Pages 6254-6260

  Meijboom, M J ^a,b   Pouwels, K B ^a   Luytjes, W ^c   Postma, M J ^a   Hak, E ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Cost effectiveness; Netherlands; Respiratory syncitial virus; Vaccination elderly

Indexed keywords

ANTIBIOTIC AGENT; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG DESIGN; GERIATRICS; GROUPS BY AGE; HEALTH CARE COST; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; LIFE EXPECTANCY; NETHERLANDS; PRESCRIPTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VACCINATION;

COST-EFFECTIVENESS; NETHERLANDS; RESPIRATORY SYNCITIAL VIRUS; VACCINATION ELDERLY;

AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; QUALITY OF LIFE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES;

EID: 84888436109     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.023     Document Type: Article

References (47)

1. Falsey A.R., Hennessey P.A., Formica M.A., Cox C., Walsh E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005 Apr 28, 352(17):1749-1759.
2. Falsey A.R., McCann R.M., Hall W.J., Tanner M.A., Criddle M.M., Formica M.A., et al. Acute respiratory tract infection in daycare centers for older persons. J Am Geriatr Soc 1995, 43(January (1)):30-36.
3. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289(January (2)):179-186.
4. Dowell S.F., Anderson L.J., Gary H.E., Erdman D.D., Plouffe J.F., File T.M., et al. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J Infect Dis 1996 Sep, 174(3):456-462.
5. Hall C.B., Walsh E.E., Long C.E., Schnabel K.C. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991, 163(April (4)):693-698.
6. Henderson F.W., Collier A.M., Clyde W.A., Denny F.W. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 1979, 300(March (10)):530-534.
7. Meijboom M.J., Rozenbaum M.H., Benedictus A., Luytjes W., Kneyber M.C., Wilschut J.C., et al. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in the Netherlands. Vaccine 2012, 30(June (31)):4691-4700.
8. Falsey A.R. Respiratory syncytial virus infection in adults. Semin Respir Crit Care Med 2007 Apr, 28(2):171-181.
9. Falsey A.R., Walsh E.E. Humoral immunity to respiratory syncytial virus infection in the elderly. J Med Virol 1992, 36(January (1)):39-43.
10. Gessner B.D. The cost-effectiveness of a hypothetical respiratory syncytial virus vaccine in the elderly. Vaccine 2000, 18(February (15)):1485-1494.
11. Falsey A.R., Treanor J.J., Betts R.F., Walsh E.E. Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J Am Geriatr Soc 1992, 40(February (2)):115-119.
12. Jackson M.M., Fierer J., Barrett-Connor E., Fraser D., Klauber M.R., Hatch R., et al. Intensive surveillance for infections in a three-year study of nursing home patients. Am J Epidemiol 1992, 135(March (6)):685-696.
13. Jansen A.G., Sanders E.A., Hoes A.W., van Loon A.M., Hak E. Influenza- and respiratory syncytial virus-associated mortality and hospitalisations. Eur Respir J 2007, 30(December (6)):1158-1166.
14. Grubeck-Loebenstein B., Berger P., Saurwein-Teissl M., Zisterer K., Wick G. No immunity for the elderly. Nat Med 1998, 4(August (8)):870.
15. Levine M.M., Sztein M.B. Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol 2004, 5(May (5)):460-464.
16. Weinberger B., Herndler-Brandstetter D., Schwanninger A., Weiskopf D., Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 2008, 46(April (7)):1078-1084.
17. Goodwin K., Viboud C., Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006, 24(February (8)):1159-1169.
18. Tacken M., Mulder J., van den Hoogen H., Tiersma W., Donkers J., Verheij R., et al. Monitoring nationaal programma grieppreventie 2008. Appendix 1 2009, 35-36. LHV, NHG, NIVEL, IQ Healthcare, Utrecht, Nijmegen.
19. Jansen A.G., Sanders E.A., Wallinga J., Groen E.J., van Loon A.M., Hoes A.W., et al. Rate-difference method proved satisfactory in estimating the influenza burden in primary care visits. J Clin Epidemiol 2008, 61(August (8)):803-812.
20. Assink M.D., Kiewiet J.P., Rozenbaum M.H., Van den Berg P.B., Hak E., Buskens E.J., et al. Excess drug prescriptions during influenza and RSV seasons in the Netherlands: potential implications for extended influenza vaccination. Vaccine 2009, 27(February (7)):1119-1126.
21. Anderson R.N. A method for constructing complete annual U.S. life tables. Vital Health Stat 2 2000, 129(129):1-28.
22. Nyman J.A., Barleen N.A., Dowd B.E., Russell D.W., Coons S.J., Sullivan P.W. Quality-of-life weights for the US population: Self-reported health status and priority health conditions, by demographic characteristics. Med Care 2007, 45(July (7)):618-628.
23. Hanmer J., Lawrence W.F., Anderson J.P., Kaplan R.M., Fryback D.G. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decision Making 2006, 26(July-August (4)):391-400.
24. Sullivan P.W., Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decision Making 2006, 26(July-August (4)):410-420.
25. Hak E. The prevention of influenza, surveillance and management (PRISMA) study. Rapport nationaal programma grieppreventie: Het success van de griepprik 2003, CVZ, Diemen.
26. van den Akker M., Buntinx F., Metsemakers J.F., Roos S., Knottnerus J.A. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol 1998, 51(May (5)):367-375.
27. Fortin M., Hudon C., Haggerty J., Akker M., Almirall J. Prevalence estimates of multimorbidity: a comparative study of two sources. BMC Health Serv Res 2010, 10(May):111.
28. Melse J.M., Essink-Bot M.L., Kramers P.G., Hoeymans N. A national burden of disease calculation: Dutch disability-adjusted life-years. dutch burden of disease group. Am J Public Health 2000, 90(August (8)):1241-1247.
29. Hakkaart-van Rooijen L., Tan S., Bouwmans C. Handleiding voor kostenonderzoek. methoden en standaardprijzen voor economische evaluaties in de gezondheidszorg 2010, CVZ, Diemen.
30. Akkerman A.E., Kuyvenhoven M.M., Verheij T.J., van Dijk L. Antibiotics in Dutch general practice: Nationwide electronic GP database and national reimbursement rates. Pharmacoepidemiol. Drug Saf. 2008, 17(April (4)):378-383.
31. Farmacotherapeutisch kompas [Internet]; 2013. Available from: http://www.farmacotherapeutischkompas.nl/.
32. Plotkin S.A.O.W. Vaccines 2004, Elsevier Inc, Philadelphia. 4th ed.
33. Fleming D.M., Elliot A.J., Cross K.W. Morbidity profiles of patients consulting during influenza and respiratory syncytial virus active periods. Epidemiol. Infect. 2007, 135(October (7)):1099-1108.
34. van Hoek A.J., Underwood A., Jit M., Miller E., Edmunds W.J. The impact of pandemic influenza H1N1 on health-related quality of life: a prospective population-based study. PLoS One 2011, 6(March (3)):e17030.
35. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89(April (4)):422-434.
36. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., Stewart C.E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969, 89(April (4)):405-421.
37. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M., Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969, 89(April (4)):435-448.
38. Chin J., Magoffin R.L., Shearer L.A., Schieble J.H., Lennette E.H. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969, 89(April (4)):449-463.
39. Longini I.M., Halloran M.E. Strategy for distribution of influenza vaccine to high-risk groups and children. Am J Epidemiol 2005, 161(February (4)):303-306.
40. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348(May (18)):1737-1746.
41. Van der Linden M., Westert G., de Bakker D., Schellevis F. Tweede nationale studie naar ziekten en verrichtingen in de huisartspraktijk. klachten en aandoeningen in de bevolking en in de huisartspraktijk 2004, NIVEL/RIVM, Utrecht/Bilthoven.
42. Kang E.J., Ko S.K. A catalogue of EQ-5D utility weights for chronic diseases among noninstitutionalized community residents in Korea. Value Health 2009, 12(November-December (Suppl. 3)):S114-S117.
43. Sisk J.E., Whang W., Butler J.C., Sneller V.P., Whitney C.G. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003, 138(June (12)):960-968.
44. Erickson P., Wilson R., Shannon I. Years of healthy life. Healthy People 2000 Stat Notes 1995, 7(April (7)):1-15.
45. Lee B.Y., Tai J.H., Bailey R.R., Smith K.J. The timing of influenza vaccination for older adults (65 years and older). Vaccine 2009, 27(November (50)):7110-7115.
46. Cals J.W., Butler C.C., Hopstaken R.M., Hood K., Dinant G.J. Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial. BMJ 2009, 338(May):b1374.
47. Uijen A.A., van de Lisdonk E.H. Multimorbidity in primary care: Prevalence and trend over the last 20 years. Eur J Gen Pract 2008, 14(Suppl 1):28-32.